Epigenetics Testing: Methods, Applications, and Interpretation

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Epigenetics Testing

What Is Epigenetics?

Epigenetics refers to heritable, reversible changes in gene expression that do not involve alterations to the underlying DNA sequence. The term, coined by Conrad Waddington in 1942, originally described how genotypes give rise to phenotypes during development. Today, epigenetics encompasses a suite of molecular mechanisms—DNA methylation, histone post-translational modifications, chromatin remodeling, and non-coding RNA-mediated regulation—that collectively determine which genes are active in a given cell at a given time. Unlike genetic mutations, epigenetic marks are dynamic and responsive to environmental cues, including diet, stress, toxins, and aging. For a broader conceptual foundation, see Epigenetics Explained and the formal Epigenetics Definition.

Epigenetics testing is the experimental measurement of these marks. It asks not "what is the sequence?" but "how is the sequence packaged and read?" A classic example is X-chromosome inactivation in female mammals, where one X chromosome is largely silenced by a combination of DNA methylation and histone modifications. Another is genomic imprinting, where genes such as IGF2 or H19 are expressed from only one parental allele based on parent-of-origin-specific methylation patterns. These phenomena demonstrate that identical DNA sequences can produce profoundly different phenotypes depending on their epigenetic state.

Why Test Epigenetic Marks?

Epigenetic testing serves three broad purposes. First, it provides mechanistic insight into gene regulation. By mapping where methylation or histone modifications occur, researchers can infer which regulatory elements—promoters, enhancers, insulators—are active in a particular cell type. Second, epigenetic marks serve as biomarkers. Because they are stable in accessible tissues like blood or saliva and often change early in disease processes, they can indicate disease risk, diagnosis, or prognosis. Third, epigenetic testing can reveal environmental exposures or developmental history, a field sometimes called "molecular archaeology." For instance, the epigenetic consequences of early-life adversity have been documented in candidate genes such as the glucocorticoid receptor gene NR3C1, linking Epigenetics Trauma to measurable molecular changes. Understanding why these marks matter is central to Epigenetics Important.

Types of Epigenetic Modifications

DNA Methylation

DNA methylation is the most extensively studied epigenetic modification. It involves the covalent addition of a methyl group (–CH₃) to the fifth carbon of cytosine, producing 5-methylcytosine (5mC). In mammals, this reaction is catalyzed by DNA methyltransferases (DNMTs): DNMT3A and DNMT3B establish new methylation patterns de novo, while DNMT1 maintains them during DNA replication by copying methylation from the parental strand to the daughter strand. The reaction uses S-adenosylmethionine (SAM) as the methyl donor.

Methylation occurs predominantly at CpG dinucleotides—cytosine followed by guanine. CpG dinucleotides are underrepresented genome-wide, but they cluster in regions called CpG islands, often found in gene promoters. Approximately 60–80% of human gene promoters contain CpG islands. When a promoter CpG island is methylated, transcription is typically repressed, either by directly impeding transcription factor binding or by recruiting methyl-binding domain proteins (e.g., MeCP2) that bring in histone deacetylases and chromatin-compacting complexes. Conversely, gene-body methylation is often associated with active transcription, and methylation at enhancers can be either activating or repressing depending on context.

Beyond 5mC, oxidation products such as 5-hydroxymethylcytosine (5hmC), generated by the TET enzyme family, add another layer of regulatory complexity. 5hmC is enriched in embryonic stem cells and neurons and is an intermediate in active DNA demethylation.

Histone Modifications

Histones are the protein spools around which DNA wraps. The core histones—H2A, H2B, H3, and H4—form an octamer, and approximately 147 base pairs of DNA wrap around each octamer to form a nucleosome. The N-terminal tails of histones protrude from the nucleosome and are subject to numerous post-translational modifications, including acetylation, methylation, phosphorylation, ubiquitination, and crotonylation.

Histone acetylation is the best-characterized activating mark. Histone acetyltransferases (HATs) such as p300/CBP add acetyl groups to lysine residues, neutralizing the positive charge of the histone tail and weakening its interaction with negatively charged DNA. This loosens chromatin and promotes transcription. Histone deacetylases (HDACs) reverse this reaction, promoting compaction and silencing.

Histone methylation is more complex because it can be activating or repressing depending on which lysine or arginine residue is modified and how many methyl groups are added. For example, trimethylation of histone H3 at lysine 4 (H3K4me3) marks active promoters, H3K36me3 marks the bodies of actively transcribed genes, and H3K27me3 is a hallmark of facultative heterochromatin and Polycomb-mediated silencing. H3K9me3 marks constitutive heterochromatin, such as centromeres and telomeres. These marks are written by histone methyltransferases (e.g., EZH2 for H3K27me3, SUV39H1 for H3K9me3) and erased by demethylases (e.g., LSD1, JmjC-domain proteins).

Non-Coding RNAs

Non-coding RNAs (ncRNAs) participate in epigenetic regulation through several mechanisms. MicroRNAs (miRNAs), ~22 nucleotides long, post-transcriptionally silence mRNAs by guiding the RNA-induced silencing complex (RISC) to complementary sequences, typically in the 3′ untranslated region. Long non-coding RNAs (lncRNAs), >200 nucleotides, can recruit chromatin-modifying complexes to specific genomic loci. The paradigmatic example is XIST, which coats the inactive X chromosome and recruits Polycomb repressive complex 2 (PRC2) to deposit H3K27me3. Another example is HOTAIR, which scaffolds PRC2 and LSD1 to target genes. While ncRNAs are not always classified as "epigenetic" in the strictest sense, they are integral to the epigenetic regulatory network and are increasingly included in epigenetic testing panels.

Methods for DNA Methylation Analysis

Bisulfite Sequencing

Bisulfite conversion is the gold-standard chemical treatment for distinguishing methylated from unmethylated cytosines. Treatment of denatured DNA with sodium bisulfite (typically 3–4 M, pH 5.0, at 50–55°C for 4–16 hours) deaminates unmethylated cytosines to uracil, while 5-methylcytosine remains unchanged. After PCR amplification, uracils are read as thymines, so the sequence of bisulfite-treated DNA reveals methylation status at single-nucleotide resolution: a retained cytosine indicates methylation; a thymine indicates unmethylated cytosine.

Whole-genome bisulfite sequencing (WGBS) applies this approach genome-wide. After bisulfite conversion, the DNA is subjected to next-generation sequencing, and bioinformatics pipelines align the reads to a reference genome, counting C/T ratios at each CpG. WGBS provides comprehensive coverage but is costly and computationally demanding. Reduced representation bisulfite sequencing (RRBS) enriches for CpG-dense regions by digesting genomic DNA with a restriction enzyme such as MspI (which cuts at CCGG sites), size-selecting fragments (typically 40–220 bp), and then performing bisulfite conversion and sequencing. RRBS covers roughly 5–10% of CpGs but focuses on promoters and CpG islands, making it a cost-effective alternative.

Methylation Arrays

Array-based platforms offer a high-throughput, cost-effective means of profiling DNA methylation at pre-selected loci. The Illumina Infinium MethylationEPIC BeadChip (the "EPIC array") interrogates over 850,000 CpG sites across the human genome, covering promoters, enhancers, gene bodies, and CpG islands. The assay uses two probe types: Type I probes measure methylation at a single CpG using two bead types (one for methylated, one for unmethylated), while Type II probes use a single bead type with different fluorescent signals for methylated versus unmethylated alleles. After hybridization and single-base extension, the ratio of fluorescent intensities is converted to a beta value (β), ranging from 0 (fully unmethylated) to 1 (fully methylated).

The EPIC array is the workhorse of epigenome-wide association studies (EWAS) because it balances genome coverage, cost, and throughput. However, it only assays known CpGs and cannot detect novel methylation sites or distinguish 5mC from 5hmC without additional processing.

Pyrosequencing

Pyrosequencing is a quantitative, targeted method for measuring methylation at specific CpG sites. Following bisulfite conversion and PCR amplification of a region of interest (typically 100–300 bp), the amplicon is subjected to pyrosequencing, a sequencing-by-synthesis method that detects pyrophosphate release as nucleotides are incorporated. The ratio of C to T at each CpG position is quantified, yielding a percentage methylation value for each site. Pyrosequencing is highly reproducible, requires only 10–50 ng of input DNA, and is widely used for clinical biomarker validation. Its main limitation is throughput: it interrogates only short, targeted regions.

The following table summarizes the key characteristics of these methods:

Methods for Histone Modification Analysis

ChIP-seq

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) is the standard method for genome-wide mapping of histone modifications and transcription factor binding sites. The protocol involves several ordered steps:

1. Crosslinking: Cells are treated with formaldehyde (typically 1% final concentration) for 10 minutes at room temperature to covalently crosslink proteins to DNA. The reaction is quenched with glycine (0.125 M).
2. Cell lysis and chromatin fragmentation: Cells are lysed, and chromatin is sheared into fragments of 200–600 bp, either by sonication (e.g., 10–20 cycles of 30 seconds on/30 seconds off at high power) or by enzymatic digestion with micrococcal nuclease (MNase).
3. Immunoprecipitation: Sheared chromatin is incubated with an antibody specific to the histone modification of interest (e.g., anti-H3K4me3, anti-H3K27ac) coupled to protein A/G magnetic beads. Incubation is typically performed overnight at 4°C with rotation.
4. Washing and elution: Beads are washed to remove non-specific binding, and chromatin is eluted with a buffer containing SDS (e.g., 1% SDS, 0.1 M NaHCO₃).
5. Reverse crosslinking and DNA purification: Samples are incubated at 65°C for 4–6 hours to reverse crosslinks, treated with proteinase K, and DNA is purified by column or phenol-chloroform extraction.
6. Library preparation and sequencing: Purified DNA is end-repaired, A-tailed, ligated to adapters, PCR-amplified (typically 12–15 cycles), and sequenced on a high-throughput platform.

The resulting sequencing reads are aligned to the reference genome, and peaks of enrichment are identified using algorithms such as MACS2. ChIP-seq requires a high-quality, modification-specific antibody; validation by western blot or dot blot is essential. Input chromatin (without immunoprecipitation) is used as a control to correct for sequencing biases and chromatin accessibility.

A related technique, ChIP-qPCR, measures enrichment at a single locus using quantitative PCR and is useful for validation. CUT&Tag (Cleavage Under Targets and Tagmentation) is a newer alternative that uses a protein A-Tn5 transposase fusion to tag DNA at antibody-targeted sites, requiring far fewer cells (as few as 100) than traditional ChIP-seq (which typically requires 10⁵–10⁷ cells).

ATAC-seq for Chromatin Accessibility

Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) maps open chromatin regions—areas where nucleosomes are depleted and regulatory proteins can bind. The method exploits the hyperactive Tn5 transposase, which preferentially inserts sequencing adapters into accessible DNA. The protocol is rapid and requires only 50,000–100,000 cells:

1. Cells are lysed to release nuclei.
2. Nuclei are incubated with Tn5 transposase loaded with sequencing adapters for 30 minutes at 37°C.
3. The transposase simultaneously fragments accessible DNA and ligates adapters.
4. DNA is purified, PCR-amplified (typically 5–10 cycles), and sequenced.

ATAC-seq reads cluster at promoters, enhancers, and insulators. By comparing ATAC-seq profiles across conditions, researchers can identify regulatory elements that change accessibility during differentiation, disease, or drug treatment. ATAC-seq can be combined with ChIP-seq to link chromatin accessibility with specific histone modifications. For example, an open chromatin peak at a gene promoter that also shows H3K27ac enrichment and H3K4me3 is strong evidence of an active promoter.

Genome-Wide Epigenetic Profiling

EWAS

Epigenome-wide association studies (EWAS) are the epigenetic analog of genome-wide association studies (GWAS). In a typical EWAS, DNA methylation is measured at hundreds of thousands of CpG sites across a large cohort (hundreds to thousands of individuals) using methylation arrays. The goal is to identify CpG sites whose methylation levels are associated with a phenotype of interest—disease status, exposure, age, or treatment response—while adjusting for covariates such as age, sex, cell-type composition, and batch effects.

A landmark example is the identification of epigenetic clocks, such as Horvath's clock, which uses methylation at 353 CpG sites to estimate biological age. Deviations between epigenetic age and chronological age have been associated with mortality, cancer risk, and neurodegenerative disease. EWAS have also identified differentially methylated positions (DMPs) in smoking, where CpGs in genes such as AHRR and F2RL3 show consistent hypomethylation in smokers. These findings illustrate how Change Epigenetics can be induced by environmental factors.

A key challenge in EWAS is cell-type heterogeneity. Blood, for example, contains multiple cell types (T cells, B cells, monocytes, neutrophils), each with distinct methylation profiles. If case and control groups differ in cell-type composition, spurious associations can arise. Statistical deconvolution methods, such as the Houseman algorithm, estimate cell-type proportions from methylation data and include them as covariates.

Integrative Multi-Omics

Epigenetic marks do not act in isolation. Integrative multi-omics approaches combine DNA methylation, histone modification, chromatin accessibility, transcriptomics (RNA-seq), and sometimes proteomics to build a comprehensive regulatory picture. For example, a typical integrative analysis might ask: does promoter methylation correlate with reduced gene expression? Is an enhancer marked by H3K27ac and accessible by ATAC-seq active in a specific cell type?

Computational tools such as the ENCODE (Encyclopedia of DNA Elements) and Roadmap Epigenomics projects have generated reference epigenomes for hundreds of cell types, providing a framework for interpreting new data. These projects have defined chromatin states—combinations of histone modifications that correspond to active promoters, enhancers, insulators, transcribed regions, and repressed regions—using hidden Markov models. For instance, an active promoter state is characterized by H3K4me3 and H3K27ac, while a poised enhancer is marked by H3K4me1 alone and an active enhancer by H3K4me1 plus H3K27ac.

Clinical Applications of Epigenetics Testing

Cancer Biomarkers

Epigenetic alterations are hallmarks of cancer. Global hypomethylation, particularly at repetitive elements such as LINE-1 and Alu, contributes to genomic instability. Concurrently, hypermethylation of CpG island promoters silences tumor suppressor genes. For example, MGMT promoter methylation silences the DNA repair enzyme O⁶-methylguanine-DNA methyltransferase, and its methylation status predicts response to temozolomide in glioblastoma. CDKN2A (p16) promoter methylation is common in many cancers and leads to loss of cell-cycle control. MLH1 promoter methylation causes microsatellite instability in colorectal and endometrial cancers.

These findings have been translated into clinical assays. The Epi proColon test detects SEPT9 promoter methylation in plasma cell-free DNA for colorectal cancer screening. The Cologuard test combines BMP3 and NDRG4 methylation with a fecal immunochemical test. In lung cancer, SHOX2 and RASSF1A methylation in bronchial aspirates or plasma are under evaluation. Methylation-based liquid biopsies are particularly attractive because they are non-invasive and can detect cancer at early stages.

Epigenetic testing also informs prognosis and treatment selection. In diffuse large B-cell lymphoma, CIITA methylation is associated with reduced survival. In breast cancer, the PAM50 assay, though primarily expression-based, is complemented by methylation signatures that stratify molecular subtypes. The FDA has approved several epigenetic tests, and many more are in development.

Non-Invasive Prenatal Testing

Fetal DNA circulates in maternal plasma as cell-free DNA (cfDNA). A fraction of this DNA originates from the placenta and carries the fetal epigenome. Non-invasive prenatal testing (NIPT) for aneuploidy, such as trisomy 21, typically relies on DNA sequencing to detect chromosomal copy number. However, epigenetic approaches offer an alternative: the placenta has a distinctive methylation pattern at specific loci. For example, the HLCS (holocarboxylase synthetase) gene promoter is hypomethylated in placental DNA but hypermethylated in maternal blood cells. By measuring the ratio of methylated to unmethylated HLCS in maternal plasma, one can estimate the fetal fraction and detect trisomy 21, which shows a gene-dosage-dependent increase in placental-derived hypomethylated DNA.

Epigenetic NIPT is also being explored for monitoring placental function. Preeclampsia, a hypertensive disorder of pregnancy, is associated with altered methylation of genes such as PAPPA and FLT1 in placental tissue, and these changes may be detectable in maternal blood before clinical symptoms appear.

Personalized Medicine

Epigenetic testing is increasingly integrated into personalized medicine. In pharmacoepigenetics, methylation of drug-metabolizing enzyme genes can influence drug response. For example, methylation of CYP1A2 or CYP2D6 promoters may alter enzyme expression and thus drug clearance. In psychiatry, methylation of the serotonin transporter gene SLC6A4 has been associated with antidepressant response, though clinical utility remains under investigation. In oncology, MGMT methylation testing guides temozolomide use in glioblastoma, and DPYD methylation is being explored as a predictor of fluoropyrimidine toxicity.

Epigenetic marks also mediate the long-term effects of environmental exposures, raising the possibility of using epigenetic profiles to guide lifestyle interventions. For instance, Epigenetics Psychology explores how psychological states and interventions may alter epigenetic marks, and Epigenetics in Humans documents the breadth of these effects. Whether such information can meaningfully guide clinical decisions remains an active area of research.

Data Analysis and Interpretation

Processing Pipelines

Epigenetic data analysis requires specialized bioinformatics pipelines. For DNA methylation arrays, the standard pipeline includes:

1. Quality control: Examine raw intensity values, remove samples with poor detection p-values, and check for sex mismatches using X/Y chromosome probes.
2. Normalization: Apply methods such as functional normalization or quantile normalization to correct for technical variation between arrays. Beta values are often converted to M-values (log2 ratio of methylated to unmethylated intensities) for statistical analysis, as M-values are more homoscedastic.
3. Batch correction: Use tools like ComBat to remove batch effects if samples were processed in multiple batches.
4. Differential methylation analysis: Fit linear models (e.g., using the limma package in R) to identify CpGs whose methylation differs between groups, adjusting for covariates.
5. Annotation and pathway analysis: Map significant CpGs to genes, promoters, enhancers, and CpG islands, and perform enrichment analysis to identify biological pathways.

For ChIP-seq data, the pipeline includes read alignment (e.g., with Bowtie2 or BWA), peak calling (MACS2), and differential binding analysis (DiffBind). Quality metrics include the fraction of reads in peaks (FRiP) and the library complexity. For ATAC-seq, additional steps include removing mitochondrial reads and correcting for Tn5 insertion bias by shifting reads.

Statistical Considerations

Epigenetic data present unique statistical challenges. The number of tested CpG sites is large (850,000 on the EPIC array), so multiple testing correction is essential. The Benjamini-Hochberg false discovery rate (FDR) is standard, with FDR < 0.05 considered significant. However, effect sizes in EWAS are often small (e.g., 1–5% methylation difference), so large sample sizes are needed for adequate power.

Confounding is a major concern. Age, sex, genetic ancestry, smoking, and cell-type composition all affect methylation and must be adjusted for. Population stratification can be addressed by including principal components from genotype data. Additionally, reverse causation is possible: disease may cause methylation changes rather than the reverse. Mendelian randomization, which uses genetic variants as instrumental variables, can help establish causal direction.

Common Pitfalls and Best Practices

Technical Artifacts

Several technical artifacts can compromise epigenetic experiments. In bisulfite conversion, incomplete conversion leads to false-positive methylation calls. Including a fully unmethylated control (e.g., PCR-amplified DNA, which is unmethylated) and a fully methylated control (e.g., CpG methyltransferase-treated DNA) is essential. Conversion efficiency should be >98%; if lower, the experiment should be repeated.

In ChIP-seq, antibody quality is the single most important factor. Many commercial antibodies recognize multiple histone modifications or cross-react with other proteins. Validation by peptide dot blot or western blot is mandatory. Additionally, over-sonication can shear chromatin too finely, reducing signal, while under-sonication leaves large fragments that increase background. The optimal fragment size is 200–600 bp.

In methylation arrays, probe polymorphisms can cause false signals. If a CpG site overlaps a single-nucleotide polymorphism (SNP), the probe may not hybridize equally across genotypes. Many analysis pipelines include SNP filtering. Similarly, cross-reactive probes that map to multiple genomic locations should be removed.

Confounding Factors

Cell-type composition is a pervasive confounder in epigenetic studies using heterogeneous tissues. In blood, the proportion of neutrophils, lymphocytes, and monocytes varies between individuals and can change with disease. If not adjusted, these differences can produce spurious associations. Reference-based deconvolution (using purified cell-type methylation profiles) or reference-free methods should be applied.

Genetic variation can also mimic or mask epigenetic effects. A SNP that creates or destroys a CpG site (a "CpG-SNP") will alter methylation measurements regardless of true epigenetic state. These sites should be identified and either excluded or analyzed separately. Additionally, methylation quantitative trait loci (mQTLs)—genetic variants that influence methylation at distant sites—can confound associations if not accounted for.

Finally, interpretation requires caution. Methylation at a promoter does not always equate to gene silencing; the relationship depends on CpG density, the specific transcription factors involved, and the broader chromatin context. Correlation between methylation and expression is often modest, and functional validation (e.g., by CRISPR-based epigenetic editing) is needed to establish causality.

Frequently Asked Questions

What is epigenetics testing?

Epigenetics testing is the measurement of chemical modifications to DNA and chromatin that regulate gene expression without changing the DNA sequence. The most common targets are DNA methylation at CpG sites, histone post-translational modifications, and chromatin accessibility. These tests are used in research, clinical diagnostics, and increasingly in personalized medicine to detect disease, predict prognosis, or monitor treatment response.

How is DNA methylation tested?

DNA methylation is most commonly tested using bisulfite conversion, which converts unmethylated cytosines to uracil while leaving methylated cytosines intact. The converted DNA is then analyzed by sequencing (WGBS or RRBS), methylation arrays (e.g., Illumina EPIC), or targeted methods like pyrosequencing or methylation-specific PCR. Each method balances genome coverage, cost, throughput, and input DNA requirements.

What is ChIP-seq used for?

ChIP-seq (chromatin immunoprecipitation followed by sequencing) is used to map the genome-wide locations of histone modifications, transcription factors, and other chromatin-associated proteins. It involves crosslinking proteins to DNA, fragmenting chromatin, immunoprecipitating with a specific antibody, and sequencing the enriched DNA. ChIP-seq reveals which genomic regions are active promoters, enhancers, or repressed chromatin in a given cell type or condition.

Can epigenetic tests diagnose cancer?

Yes, some epigenetic tests are clinically validated for cancer diagnosis and screening. For example, SEPT9 promoter methylation in plasma is approved for colorectal cancer screening, and MGMT promoter methylation guides treatment in glioblastoma. Many other methylation-based assays are in development for early detection, subtyping, and prognosis across cancer types. However, most require validation in large prospective cohorts before regulatory approval.

What is the difference between genetics and epigenetics testing?

Genetics testing examines the DNA sequence itself—mutations, insertions, deletions, copy number changes—to identify inherited or somatic variants. Epigenetics testing measures reversible chemical modifications on top of the DNA sequence, such as methylation or histone modifications, that affect gene activity without altering the sequence. Genetics testing is static (the sequence does not change), while epigenetic marks are dynamic and responsive to environment, age, and disease.

What are common pitfalls in epigenetic data analysis?

Common pitfalls include inadequate bisulfite conversion, poor antibody specificity in ChIP-seq, failure to adjust for cell-type composition, ignoring genetic variants that affect CpG sites, insufficient multiple testing correction, and overinterpreting correlation as causation. Batch effects and technical variability between processing runs are also frequent problems. Best practices include rigorous quality control, appropriate normalization, validation in independent cohorts, and functional follow-up experiments.

Key Takeaways

• Epigenetics testing measures DNA methylation, histone modifications, and chromatin accessibility—reversible marks that regulate gene expression without altering the DNA sequence.
• DNA methylation analysis relies heavily on bisulfite conversion, with methods ranging from whole-genome bisulfite sequencing to targeted pyrosequencing and high-throughput methylation arrays.
• ChIP-seq and ATAC-seq are the principal methods for mapping histone modifications and chromatin accessibility genome-wide, respectively.
• Epigenome-wide association studies (EWAS) link methylation patterns to phenotypes, but require careful adjustment for cell-type composition, batch effects, and genetic confounders.
• Clinical applications include cancer biomarkers (e.g., SEPT9, MGMT), non-invasive prenatal testing, and pharmacoepigenetic guidance for drug response.
• Epigenetic marks are dynamic and environmentally responsive, providing a molecular interface between exposures and phenotype, as explored in Epigenetics Inherited and related topics.
• Rigorous experimental design, quality control, and statistical analysis are essential to avoid artifacts and produce reproducible epigenetic findings.

Related Clinical & Scientific Guides

• MAPK Pathway: Mechanism, Function, and Clinical Relevance
• Mammalian Cell Culture Bioreactors: A Practical Guide
• Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks